OTCPK:CYCA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cytta Corp. is engaged in the manufacture, distribution, and marketing of various telephony based Internet access and computing products and services in the eHealth industry. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Cytta's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CYCA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.8%

CYCA

1.5%

US Healthcare Services

-1.9%

US Market


1 Year Return

246.0%

CYCA

57.8%

US Healthcare Services

13.1%

US Market

Return vs Industry: CYCA exceeded the US Healthcare Services industry which returned 57.8% over the past year.

Return vs Market: CYCA exceeded the US Market which returned 13.1% over the past year.


Shareholder returns

CYCAIndustryMarket
7 Day1.8%1.5%-1.9%
30 Day15.3%0.9%-2.9%
90 Day103.5%12.6%8.2%
1 Year246.0%246.0%58.2%57.8%15.7%13.1%
3 Year147.1%147.1%101.1%99.8%38.4%29.1%
5 Year260.4%260.4%163.7%161.3%89.3%68.0%

Price Volatility Vs. Market

How volatile is Cytta's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cytta undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Cytta is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cytta has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Cytta's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Cytta regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Cytta forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

38.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cytta has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine Cytta's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Cytta's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Cytta performed over the past 5 years?

22.9%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Cytta has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Cytta's financial position?


In this section we usually analyse Cytta's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Cytta has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of CYCA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Cytta's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Cytta current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CYCA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CYCA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYCA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYCA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYCA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average management tenure


CEO

Gary Campbell (66 yo)

10.25yrs

Tenure

US$180,000

Compensation

Mr. Gary Campbell, B.Comm., LL.B., serves as the Chief Executive Officer of Cytta Corp. since June 2010 and has been its Treasurer since November 15, 2010 and Secretary since March 12, 2010. Mr. Campbell s ...


Leadership Team

NamePositionTenureCompensationOwnership
Gary Campbell
Chairman10.25yrsUS$180.00kno data
Erik Stephansen
President & Director7.33yrsUS$187.50kno data
Daniel Jacoy
Vice President of Finance & Business Strategy3.58yrsno datano data
Ted Fellerman
Chief Investment Officer4.92yrsno datano data
Lee Skoblow
Vice President of Investor Relations & Market Strategyno datano datano data
Michael Collins
Chief Visionary Officer & Director of Digital Mediano datano datano data

4.9yrs

Average Tenure

Experienced Management: CYCA's management team is considered experienced (4.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gary Campbell
Chairman10.25yrsUS$180.00kno data
Erik Stephansen
President & Director7.33yrsUS$187.50kno data
William Nance
Member of Board of Corporate Advisors4.92yrsno datano data
Marilyn Harz
Member of Board of Advisorsno datano datano data
Natalia Sokolova
Directorno datano datano data
Darren Pleasance
Member of Board of Advisorsno datano datano data
Harvey Sussman
Member of Board of Advisorsno datano datano data
Ross McCabe
Member of Board of Medical Advisorsno datano datano data
David Mescher
Member of Board of Medical Advisorsno datano datano data
Terrence Olson
Member of Board of Medical Advisorsno datano datano data
Christian Reichardt
Member of Board of Medical Advisorsno datano datano data
Nicholas Donoghoe
Member of Board of Medical Advisorsno datano datano data

4.9yrs

Average Tenure

61yo

Average Age

Experienced Board: CYCA's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 55.8%.


Top Shareholders

Company Information

Cytta Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cytta Corp.
  • Ticker: CYCA
  • Exchange: OTCPK
  • Founded: 2006
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$25.011m
  • Shares outstanding: 289.15m
  • Website: https://www.cytta.com

Number of Employees


Location

  • Cytta Corp.
  • 6490 West Desert Inn Road
  • Las Vegas
  • Nevada
  • 89146
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYCAOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDOct 2007

Biography

Cytta Corp. is engaged in the manufacture, distribution, and marketing of various telephony based Internet access and computing products and services in the eHealth industry. The company delivers health an ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/24 07:57
End of Day Share Price2020/09/23 00:00
Earnings2014/06/30
Annual Earnings2013/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.